NO994390D0 - Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors - Google Patents

Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors

Info

Publication number: NO994390D0
Authority: NO; Norway
Prior art keywords: benzothepines; hmg; combination therapy; bile acid; reductase inhibitors
Prior art date: 1997-03-11

Application number

NO994390A

Other languages

Norwegian (no)

Other versions

NO994390L (en

Inventor

David B Reitz

Len F Lee

Jinglin J Li

Horng-Chih Huang

Samuel J Tremont

Raymond E Miller

Shyamal C Baneriee

Robert E Manning

Kevin C Glenn

Bradley T Keller

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-11

Filing date

1999-09-10

Publication date

1999-09-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994390(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-10 Application filed by Searle & Co filed Critical Searle & Co

1999-09-10 Publication of NO994390D0 publication Critical patent/NO994390D0/en

1999-11-04 Publication of NO994390L publication Critical patent/NO994390L/en

Links

HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
239000003613 bile acid Substances 0.000 title 1
238000002648 combination therapy Methods 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

NO994390A 1997-03-11 1999-09-10 Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors NO994390L (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4066097P	1997-03-11	1997-03-11
PCT/US1998/003792 WO1998040375A2 (en)	1997-03-11	1998-03-10	COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Publications (2)

Publication Number	Publication Date
NO994390D0 true NO994390D0 (en)	1999-09-10
NO994390L NO994390L (en)	1999-11-04

Family

ID=21912237

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO994390A NO994390L (en)	1997-03-11	1999-09-10	Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors

Country Status (16)

Country	Link
EP (1)	EP0971744A2 (en)
JP (1)	JP2002500628A (en)
CN (1)	CN1255864A (en)
AU (1)	AU730024C (en)
BG (1)	BG103793A (en)
BR (1)	BR9808013A (en)
CA (1)	CA2283575A1 (en)
HU (1)	HUP0002395A3 (en)
IL (1)	IL131872A0 (en)
MX (1)	MXPA99008417A (en)
NO (1)	NO994390L (en)
NZ (1)	NZ337830A (en)
PL (1)	PL336415A1 (en)
RU (1)	RU2247579C2 (en)
SK (1)	SK125099A3 (en)
WO (1)	WO1998040375A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) *	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6083497A (en)	1997-11-05	2000-07-04	Geltex Pharmaceuticals, Inc.	Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en)	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE69908643T2 (en)	1998-12-23	2004-05-13	G.D. Searle Llc, Chicago	COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND NICOTIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS
AU2003241629B2 (en) *	1999-04-19	2005-06-16	Astrazeneca Ab	An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (en)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
US20020061888A1 (en) *	2000-03-10	2002-05-23	Keller Bradley T.	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (en) *	2000-10-18	2000-10-18	Astrazeneca Ab	Novel formulation
EG26979A (en)	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
WO2002051396A1 (en) *	2000-12-26	2002-07-04	Sankyo Company, Limited	Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
MY131995A (en)	2001-09-08	2007-09-28	Astrazeneca Ab	Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
US7202247B2 (en)	2001-12-19	2007-04-10	Atherogenics, Inc.	1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
RU2004121898A (en)	2001-12-19	2006-01-20	Атеродженикс, Инк. (Us)	CHALKONE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF DISEASES
JP2005521653A (en)	2002-01-17	2005-07-21	ファルマシアコーポレイション	Novel alkyl / arylhydroxy or ketothiepine compounds as inhibitors of advanced sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
KR100990524B1 (en) *	2002-08-28	2010-10-29	아사히 가세이 파마 가부시키가이샤	Novel Quaternary Ammonium Compounds
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
JP4711953B2 (en)	2004-02-27	2011-06-29	旭化成ファーマ株式会社	Novel benzothiazepine and benzothiepine compounds
EP4137137A1 (en)	2010-05-26	2023-02-22	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CA2815749C (en)	2010-11-04	2019-12-03	Albireo Ab	Ibat inhibitors for the treatment of liver diseases
SG190433A1 (en)	2010-11-08	2013-06-28	Albireo Ab	A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EP2770990A4 (en)	2011-10-28	2015-03-11	Lumena Pharmaceuticals Inc	BILY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF HYPERCHOLEMIA AND HEPATIC CHOLESTATIC DISEASE
PT2771003T (en)	2011-10-28	2017-07-26	Lumena Pharmaceuticals Llc	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
AU2014228850A1 (en)	2013-03-15	2015-10-29	Lumena Pharmaceuticals Llc	Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
MX2015013196A (en)	2013-03-15	2016-04-15	Lumena Pharmaceuticals Inc	Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease.
JO3301B1 (en)	2013-04-26	2018-09-16	Albireo Ab	Crystal modifications of elobixibat
JP6751020B2 (en)	2014-06-25	2020-09-02	Ｅａファーマ株式会社	Solid preparation and method for preventing or reducing coloration thereof
CN115990171A (en)	2014-09-28	2023-04-21	华辉安健（北京）生物科技有限公司	Polymeric bile acid derivatives inhibit hepatitis B virus and hepatitis D virus and NTCP transport
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
JP6954926B2 (en)	2016-02-09	2021-10-27	アルビレオ・アクチボラグ	Oral cholestyramine preparation and its use
EP3413878B1 (en)	2016-02-09	2021-04-14	Albireo AB	Oral cholestyramine formulation and use thereof
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
WO2019032027A1 (en)	2017-08-09	2019-02-14	Albireo Ab	Cholestyramine pellets, oral cholestyramine formulations and use thereof
CA3071285A1 (en)	2017-08-09	2019-02-14	Albireo Ab	Cholestyramine granules, oral cholestyramine formulations and use thereof
EP3675637A4 (en)	2017-08-28	2021-05-19	Enanta Pharmaceuticals, Inc.	ANTIVIRAL AGENTS AGAINST HEPATITIS B
TW202015699A (en)	2018-06-05	2020-05-01	瑞典商艾爾比瑞歐公司	Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
WO2019245448A1 (en)	2018-06-20	2019-12-26	Albireo Ab	Crystal modifications of odevixibat
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
SG11202105007TA (en)	2018-11-21	2021-06-29	Enanta Pharm Inc	Functionalized heterocycles as antiviral agents
MX2021008981A (en)	2019-02-06	2021-09-08	Albireo Ab	BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS.
CN118834175A (en)	2019-02-06	2024-10-25	阿尔比里奥公司	Benzothiazacycloalkanes Heptatriene compounds use thereof as bile acid modulators
US10941127B2 (en)	2019-02-06	2021-03-09	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en)	2019-02-06	2021-04-13	Aibireo AB	Benzothiazepine compounds and their use as bile acid modulators
WO2020167964A1 (en)	2019-02-12	2020-08-20	Mirum Pharmaceuticals, Inc.	Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
AR120676A1 (en)	2019-12-04	2022-03-09	Albireo Ab	BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID
WO2021110887A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
CN114761018B (en)	2019-12-04	2025-12-02	阿尔比里奥公司	Benzothiazazacycloheptatriene compounds and their uses as bile acid regulators
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
CN114761080B (en)	2019-12-04	2024-07-23	阿尔比里奥公司	Benzothia(di)azepine compounds and their use as bile acid regulators
CN114786772B (en)	2019-12-04	2024-04-09	阿尔比里奥公司	Benzothia(di)azepine compounds and their use as bile acid regulators
WO2021110884A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TWI877263B (en)	2019-12-04	2025-03-21	瑞典商艾爾比瑞歐公司	Benzothiadiazepine compounds and their use as bile acid modulators
AR120679A1 (en)	2019-12-04	2022-03-09	Albireo Ab	BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
BR112022010505A2 (en)	2019-12-04	2022-09-06	Albireo Ab	BENZOTHYA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID MODULATION
CA3186857A1 (en)	2020-08-03	2022-02-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (en)	2020-11-12	2023-11-22	アルビレオエービー	Odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC)
CN112274648B (en) *	2020-11-23	2022-10-14	郑州大学	Preparation method of a cholesterol oxidase-modified hybrid metal-organic framework tumor-targeting nanoformulation
WO2022117778A1 (en)	2020-12-04	2022-06-09	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (en)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	Benzothia(di)azepine compounds and their use as bile acid modulators
CN119343140A (en)	2022-06-09	2025-01-21	阿尔比里奥公司	Treating Hepatitis
TW202423921A (en) *	2022-08-22	2024-06-16	美商安塔製藥公司	Fused heterobicyclic antiviral agents
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444784A (en) *	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
ES2087422T3 (en) *	1991-12-20	1996-07-16	Hoechst Ag	POLYMERS AND OLIGOMERS OF BILIAR ACID DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND USE AS A MEDICINE.
GB9203347D0 (en) *	1992-02-17	1992-04-01	Wellcome Found	Hypolipidaemic compounds

1998
- 1998-03-10 MX MXPA99008417A patent/MXPA99008417A/en unknown
- 1998-03-10 PL PL98336415A patent/PL336415A1/en unknown
- 1998-03-10 WO PCT/US1998/003792 patent/WO1998040375A2/en not_active Ceased
- 1998-03-10 CA CA002283575A patent/CA2283575A1/en not_active Abandoned
- 1998-03-10 EP EP98910075A patent/EP0971744A2/en not_active Withdrawn
- 1998-03-10 RU RU99121514/15A patent/RU2247579C2/en not_active IP Right Cessation
- 1998-03-10 HU HU0002395A patent/HUP0002395A3/en unknown
- 1998-03-10 JP JP53959498A patent/JP2002500628A/en not_active Abandoned
- 1998-03-10 BR BR9808013-0A patent/BR9808013A/en not_active IP Right Cessation
- 1998-03-10 AU AU64408/98A patent/AU730024C/en not_active Ceased
- 1998-03-10 SK SK1250-99A patent/SK125099A3/en unknown
- 1998-03-10 CN CN98804995A patent/CN1255864A/en active Pending
- 1998-03-10 NZ NZ337830A patent/NZ337830A/en not_active Application Discontinuation
- 1998-03-10 IL IL13187298A patent/IL131872A0/en unknown
1999
- 1999-09-10 NO NO994390A patent/NO994390L/en not_active Application Discontinuation
- 1999-10-11 BG BG103793A patent/BG103793A/en unknown

Also Published As

Publication number	Publication date
NZ337830A (en)	2001-07-27
AU730024B2 (en)	2001-02-22
HUP0002395A3 (en)	2002-12-28
SK125099A3 (en)	2001-02-12
WO1998040375A3 (en)	1998-12-03
BG103793A (en)	2000-07-31
HUP0002395A2 (en)	2001-05-28
WO1998040375A2 (en)	1998-09-17
JP2002500628A (en)	2002-01-08
BR9808013A (en)	2001-09-25
RU2247579C2 (en)	2005-03-10
CN1255864A (en)	2000-06-07
CA2283575A1 (en)	1998-09-17
PL336415A1 (en)	2000-06-19
NO994390L (en)	1999-11-04
MXPA99008417A (en)	2005-02-03
AU730024C (en)	2004-08-05
IL131872A0 (en)	2001-03-19
EP0971744A2 (en)	2000-01-19
AU6440898A (en)	1998-09-29

Publication	Publication Date	Title
NO994390L (en)	1999-11-04	Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors
DK1105123T3 (en)	2004-08-09	Pharmaceuticals containing lipase inhibitors and chitosan
DK1216247T3 (en)	2009-02-23	Imidazoimidazoles and triazoles as anti-inflammatory agents
NO20010016D0 (en)	2001-01-02	Benzothiepines with activity as inhibitors of ileal bile acid transport and uptake of taurocholate
NO20001323D0 (en)	2000-03-14	Dipeptide-apoptosis inhibitors and their use
ZA98376B (en)	1998-07-23	Sulfamide-metalloprotease inhibitors
NO990296D0 (en)	1999-01-22	The HPPD gene and inhibitors
MXPA03003417A (en)	2003-08-07	Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor.
DK0944590T3 (en)	2002-07-15	Aminoguanidines and alkoxyguanidines as protease inhibitors
GB9801393D0 (en)	1998-03-18	Sulfamide-metalloprotease inhibitors
IS6181A (en)	2001-11-28	Single and double accessible 3-propyl-gamma amino butyric acids
NO993956L (en)	1999-10-27	Goal tracking procedure
IL135428A0 (en)	2001-05-20	Ace inhibitor-mmp inhibitor combinations
DK0914124T3 (en)	2004-05-17	Antithrombotic, antiatherosclerotic, pharmaceutical composition comprising a thienopyridine derivative and an HMG-CoA reductase inhibitor
NO20000682D0 (en)	2000-02-11	Gasket and dispenser
PT948483E (en)	2002-08-30	FARNESIL-TRANSFERASE INHIBITORS
AU9802798A (en)	1999-05-03	Gas treating solution corrosion inhibitor
AU9443898A (en)	1999-05-03	Wof inhibitor
NO20000371D0 (en)	2000-01-25	Aminoethylphenoxyacetic acid derivatives and drugs for pain reduction and limestone removal in urinary lithiasis
AUPQ180499A0 (en)	1999-08-19	Beta-amyloid peptide inhibitors
AU8968598A (en)	1999-03-29	Bovine footrot treatment and prevention
HUP0201597A3 (en)	2003-04-28	Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
EP1010892A4 (en)	2003-07-23	HELICOIDAL COMPRESSOR
DK199901135A (en)	2001-02-19	Procedure and arrangement for carrying out financial transactions
NO303034B1 (en)	1998-05-18	Receipt note for cash register and the like

Legal Events

Date	Code	Title	Description
2005-11-07	FC2A	Withdrawal, rejection or dismissal of laid open patent application